Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application
Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application
Bio-Path已启动治疗项目，开发BP1001-A用于肥胖和相关代谢性疾病，该项目标志着DNAbilize技术首次应用于非癌症应用的开发。
Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application
Bio-Path已启动治疗项目，开发BP1001-A用于肥胖和相关代谢性疾病，该项目标志着DNAbilize技术首次应用于非癌症应用的开发。
资讯热榜
更新时间